Transmission Patterns of HIV-Subtypes A/AE versus B: Inferring Risk-Behavior Trends and Treatment-Efficacy Limitations from Viral Genotypic Data Obtained Prior to and during Antiretroviral Therapy

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Avidor, Boaz ^a   Turner, Dan ^a   Mor, Zohar ^b   Chalom, Shirley ^a   Riesenberg, Klaris ^c   Shahar, Eduardo ^d   Pollack, Shimon ^d   Elbirt, Daniel ^e   Sthoeger, Zev ^e   Maayan, Shlomo ^f   Olshtain Pops, Karen ^f   Averbuch, Diana ^f   Chowers, Michal ^g   Istomin, Valery ^h   Anis, Emilia ^b   Mendelson, Ella ^b,i   Ram, Daniela ^b   Levy, Itzchak ^j   Grossman, Zehava ⁱ  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b MINISTRY OF HEALTH   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d RAMBAM MEDICAL CENTER   (Israel)

^e KAPLAN MEDICAL CENTER   (Israel)

^f HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^g MEIR MEDICAL CENTER   (Israel)

^h HILLEL YAFFE MEDICAL CENTER   (Israel)

ⁱ TEL AVIV UNIVERSITY   (Israel)

^j SHEBA MEDICAL CENTER   (Israel)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRATION; INCIDENCE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MIXED INFECTION; NUCLEOTIDE SEQUENCE; PHYLOGENY; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; SEROCONVERSION; SYPHILIS; VIRUS LOAD; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; DRUG USERS; FEMALE; GENETIC VARIATION; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; ISRAEL; MALE; MOLECULAR TYPING; PHYLOGENY; PREVALENCE; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 84874575997     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057789     Document Type: Article

References (57)

1. Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG, (2003) Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother 51: 229-240.
2. Wainberg MA, Brenner BG, (2010) Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs. Viruses 2: 2493-2508.
3. Bangsberg DR, Porco TC, Kagay C, Charlebois ED, Deeks SG, et al. (2004) Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. J Infect Dis 190: 162-165.
4. Bengtsson L, Thorson A, (2010) Global HIV surveillance among MSM: is risk behavior seriously underestimated? AIDS 24: 2301-2303.
5. Levy I, Mor Z, Anis E, Maayn S, Leshem E, et al. (2011) Men who have sex with men, risk behavior, and HIV infection: integrative analysis of clinical, epidemiological, and laboratory databases. Clin Infect Dis 52: 1363-1370.
6. Turner D, Amit S, Chalom S, Penn O, Pupko T, et al. (2011) Emergence of an HIV-1 cluster harbouring the major protease L90M mutation among treatment-naive patients in Tel Aviv, Israel. HIV Med 13: 202-206.
7. Adler MW, (1987) ABC of AIDS. Development of the epidemic. Br Med J (Clin Res Ed) 294: 1083-1085.
8. Nabatov AA, Kravchenko ON, Lyulchuk MG, Shcherbinskaya AM, Lukashov VV, (2002) Simultaneous introduction of HIV type 1 subtype A and B viruses into injecting drug users in southern Ukraine at the beginning of the epidemic in the former Soviet Union. AIDS Res Hum Retroviruses 18: 891-895.
9. Roudinskii NI, Sukhanova AL, Kazennova EV, Weber JN Pokrovsky VV, et al. (2004) Diversity of human immunodeficiency virus type 1 subtype A and CRF03_AB protease in Eastern Europe: selection of the V77I variant and its rapid spread in injecting drug user populations. J. Virol. 78: 11276-11287.
10. Saad MD, Aliev Q, Botros BA, Carr JK, Gomatos PJ, et al. (2006) Genetic forms of HIV Type 1 in the former Soviet Union dominate the epidemic in Azerbaijan. AIDS Res Hum Retroviruses 22: 796-800.
11. UNAIDS. 2010 Global Report (2011) Available: http://www.unaids.org/documents/20101123_GlobalReport/.
12. Hemelaar J, Gouws E, Ghys PD, Osmanov S, (2011) Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 25: 679-689.
13. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, et al. (2008) Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 372: 1733-1745.
14. Slater PE, Costin C, (1993) The epidemiology of adult AIDS and HIV infection in Israel. Isr J Med Sci 29: 2-6.
15. Kaplan EH, Slater PE, Soskolne V, (1995) How many HIV infections are there in Israel? Reconstructing HIV incidence from AIDS case reporting. Public Health Rev 23: 215-235.
16. Chemtob D, Grossman Z, (2004) Epidemiology of adult and adolescent HIV infection in Israel: a country of immigration. Int J STD AIDS 15: 691-696.
17. Mor Z, Pinsker G (2011) HIV/AIDS in Israel, Epidemiological Periodic Report 1981-2010. Public Health Services, Department of Tuberculosis & AIDS, MOH, Israel. Available: www.health.gov.il/TBAIDS.
18. Central Bureau of Statistics Jerusalem, the State of Israel (2010) Statistical abstract of Israel, Jerusalem. Available: http://www1.cbs.gov.il/.
19. Brenner BG, Roger M, Moisi DD, Oliveira M, Hardy I, et al. (2008) Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS 22: 2509-2515.
20. Schupbach J, Gebhardt MD, Tomasik Z, Niederhauser C, Yerly S, et al. (2007) Assessment of recent HIV-1 infection by a line immunoassay for HIV-1/2 confirmation. PLoS Med 4: e343.
21. Grossman Z, Vardinon N, Chemtob D, Alkan ML, Bentwich Z, et al. (2001) Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B. AIDS. 15: 1453-1460.
22. Kantor R, Machekano R, Gonzales MJ, Dupnik K, Schapiro JM, et al. (2001) Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Res 29: 296-299.
23. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, et al. (2003) Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 31: 298-303.
24. Rhee SY, Kantor R, Katzenstein DA, Camacho R, Morris L, et al. (2006) HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. AIDS 20: 643-651.
25. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, et al. (2009) Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: update. PLoS One 4: e4724.
26. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, et al. (2009) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28: 2731-2739.
27. Rambaut A. FigTree v1.3.1. (2009) Available: http://tree.bio.ed.ac.uk/software/figtree/.
28. Drummond AJ, Suchard MA, Xie D, Rambaut A (2012) Bayesian phylogenetics with BEAUti and the BEAST 1.7. Mol Biol Evol.
29. Collins KR, Quinones-Mateu ME, Wu M, Luzze H, Johnson JL, et al. (2002) Human immunodeficiency virus type 1 (HIV-1) quasispecies at the sites of Mycobacterium tuberculosis infection contribute to systemic HIV-1 heterogeneity. J Virol 76: 1697-1706.
30. Kearney M, Palmer S, Maldarelli F, Shao W, Polis MA, et al. (2008) Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase. AIDS 22: 497-501.
31. Grossman Z, Avidor B, Mor Z, Turner D, Levy I, et al. (2012) Identification of HIV Transmission Networks in Israel. Antiviral Therapy 17Suppl 1: A172.
32. Chemtob D, Levit S, Mell H, Margolis A, Levy A, et al. (2008) ["Injecting clean or being clean?" The international and Israeli experiences of Syringe Exchange Programs among injecting drug users]. Harefuah 147: 634-638.
33. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, et al. (2005) Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2: e112.
34. Ariyoshi K, Matsuda M, Miura H, Tateishi S, Yamada K, et al. (2003) Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection. J Acquir Immune Defic Syndr 33: 336-342.
35. Martinez-Cajas JL, Wainberg MA, Oliveira M, Asahchop EL, Doualla-Bell F, et al. (2012) The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors. J Antimicrob Chemother 67: 988-994.
36. Audelin AM, Lohse N, Obel N, Gerstoft J, Jorgensen LB, (2009) The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish cohort study 1999-2005. Antivir Ther 14: 995-1000.
37. Lohse N, Obel N, Kronborg G, Jorgensen LB, Pedersen C, et al. (2006) Declining prevalence of HIV-infected individuals at risk of transmitting drug-resistant HIV in Denmark during 1997-2004. Antivir Ther 11: 591-600.
38. Vercauteren J, Deforche K, Theys K, Debruyne M, Duque LM, et al. (2008) The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. Retrovirology 5: 12.
39. Di Giambenedetto S, Zazzi M, Corsi P, Gonnelli A, Di Pietro M, et al. (2009) Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy. Antivir Ther 14: 359-369.
40. Bartmeyer B, Kuecherer C, Houareau C, Werning J, Keeren K, et al. (2010) Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort. PLoS One 5: e12718.
41. Lataillade M, Chiarella J, Yang R, Schnittman S, Wirtz V, et al. (2010) Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study. PLoS One 5: e10952.
42. Grossman Z, Paxinos EE, Averbuch D, Maayan S, Parkin NT, et al. (2004) Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob Agents Chemother 48: 2159-2165.
43. Nikolenko GN, Delviks-Frankenberry KA, Palmer S, Maldarelli F, Fivash MJ Jr, et al. (2007) Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance. Proc Natl Acad Sci USA 104: 317-322.
44. Svicher V, Alteri C, Artese A, Forbici F, Santoro MM, et al. (2010) Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. J Acquir Immune Defic Syndr 55: 336-344.
45. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, et al. (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354: 251-260.
46. Parikh UM, Zelina S, Sluis-Cremer N, Mellors JW, (2007) Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. AIDS 21: 1405-1414.
47. Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, et al. (2008) Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 14: 762-766.
48. Sampah MES, Shen L, Jilik BL, Siliciano RF, (2011) Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance. Proc. Natl. aca. Sci. USA 108: 7613-7618.
49. Rosenbloom DIS, Hill AL, Rabi SA, Siliciano RF, Nowak MA, (2012) Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nat. Med. 18: 1378-1386.
50. Parry CM, Kohli A, Boinett CJ, Towers GJ, McCormick AL, et al. (2009) Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1. J. Virol. 83: 9094-9101.
51. Dam E, Quercia R, Glass B, Descamps D, Launay O, et al. (2009) Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog. 5, e1000345.
52. Gupta RK, Kohli A, McCormick AL, Towers GJ, Pillay, et al, (2010) Full length HIV-1 gag determines protease inhibitor susceptibility within in vitro assays. AIDS 24: 1651-1655.
53. Grossman Z, Polis M, Feinberg MB, Grossman Z, Levy I, et al. (1999) Ongoing HIV dissemination during HAART. Nat Med. 5: 1099-1104.
54. Deeks SG, Barbour JD, Grant RM, Martin JN, (2002) Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 25 16: 201-207.
55. Wainberg MA, Zaharatos GJ, Brenner BG, (2011) Development of antiretroviral drug resistance. N Engl J Med 365: 637-646.
56. Wensing AM, van de Vijver DA, Angarano G, Asjo B, Balotta C, et al. (2005) Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 192: 958-966.
57. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, et al. (2005) An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 21: 3797-3800.